published on March 23, 2020 by Lilli Zakarija
As the situation with COVID-19 is extremely dynamic, we at EdgeOne Medical are continuing to make proactive decisions that are grounded in care for our employees and their families and serving our clients. Below you will see the changes we have made to our operations due to the COVID-19 pandemic.
published on February 28, 2020 by Jim McGough
published on June 13, 2018 by Jim McGough
I was once told by a serial Life Sciences Entrepreneur (with both Biotech & MedTech exits) that when it comes to taking care of their young (early stage ventures) the Biotech industry is “mammalian” and MedTech industry is “reptilian”. In other words, Biotech/Pharma nurtures their young (In-licensing/Out-licensing deals) and MedTech eats their young (acquisition/do not commercialize).
published on August 17, 2017 by Jim McGough
The next 25 years will present incredible opportunities for innovators in the MedTech industry. In my opinion, individuals and teams who learn to operate with the “Hipster, Hacker, and Hustler” mindset will be in the best position to create game-changing innovation and become sought-after partners in future MedTech innovations. Unfortunately, this mindset is a bit foreign to many folks who have already been in the MedTech industry for a while---and professional investors “know it when they see it”.
published on March 03, 2017 by Jerzy Wojcik
This article was originally published in the March 2017 Issue of Drug, Development, and Delivery
published on March 01, 2017 by Lilli Zakarija
Earlier this month, I attended the Drug Delivery Partnerships (DDP) Conference in Florida. The conference covered a wide range of topics impacting the combination product sector including digital health, mixed reality, risk management, new technologies in manufacturing and molecular development.
published on August 10, 2016 by Lilli Zakarija
This article originally was published in the Combination Corner featured article in Drug Development & Delivery magazine on May 3, 2016
published on May 10, 2016 by Jim McGough
Your "Present" is not feeling well
You will not find your "Future" while rapidly inputting patient information into an electronic health record system portal every Friday night while sitting in close proximity to your spouse who is also a physician and doing the same thing while you both enjoy a bottle of wine, a pizza, and intermittent conversation (now known as Physician couple date night and unfortunately a true story). It is no wonder that the U.S. Surgeon General, Dr. Vivek Murthy, recently proclaimed that improving the “emotional well-being” of physicians has become one of the top priorities for the entire healthcare ecosystem.
published on September 29, 2015 by Jim McGough
You don’t plan to do it (an early exit)—but rather you design your venture to be able to do it in a win-win-win way (entrepreneur/investor/strategic acquirer) at every milestone.
published on September 18, 2015 by Jim McGough
Someone years ago shared with me the principle of "a happy wife leads to a happy life". I chuckled, acknowledged the sage advice, and stored the catch-phrase somewhere in my brain. It wasn't until I started working with my wife Lilli as co-founder of EdgeOne Medical that I realized how true this saying was. But it wasn't just about "happiness"--it was about something more. It was about significance. Her life's significance and what I could do to support and enable her pursuit of significance.
published on April 30, 2015 by Jerzy Wojcik
Today's Therapeutic-focused Combination Product (Drug/Biologic & Device) Companies: The Good, The Bad, and The Ugly. Which one are you?
published on March 02, 2015 by Lilli Zakarija
You are a drug/biologic developer and the time has come to select a delivery device (auto-injector, pump, etc.) that will be feasible for clinical trials and ideally commercialization. More than likely you are not interested in developing this device in house and you need to decide whether to develop a custom delivery device or leverage an existing “off-the-shelf” device. The points listed below serve as a guideline to facilitate the decision making process and to assist in selecting the best device for your specific needs.
published on February 28, 2015 by Jerzy Wojcik
FDA’s final rule on combination products (21 C.F.R. Part 4) set forth current good manufacturing practice requirements that must be met for the entire product (drug/device or biologic/device), regardless if the device design occurs internally or externally to the Marketing Authorization Holder (MAH). Although many elements of CP cGMPs are well understood, it appears many are focused on understanding design control and supplier evaluation in the context of the new regulation and guidance.